Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TsumuraTSMRF 79 EV-to-OCF is 15.18 as of Aug. 05, 2026, which is 6% above its 10-year median of 14.28. GuruFocus rates TSMRF with a GF Score™ of 79/100 and a GF Value™ of $25.74. The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Tsumura ranks worse than 61.71% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Tsumura's Enterprise Value is $2,421 Mil.
Tsumura's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $160 Mil. Therefore, Tsumura's EV-to-OCF for today is 15.18.
The historical rank and industry rank for Tsumura's EV-to-OCF or its related term are showing as below:
TSMRF'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.27 Med: 14.28 Max: 84.92
Current: 15.54
During the past 13 years, the highest EV-to-OCF of Tsumura was 84.92. The lowest was 8.27. And the median was 14.28.
TSMRF's EV-to-OCF is ranked worse than 61.71% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs TSMRF: 15.54
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tsumura's share price for today is $23.20.
Tsumura's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.474.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tsumura EV-to-OCF Related Terms
Tsumura EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Tsumura's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tsumura's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsumura EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tsumura's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Tsumura's EV-to-OCF falls into.
Tsumura's current Enterprise Value is $2,421 Mil.
Tsumura's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $160 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsumura (TSMRF) has a EV-to-OCF of 15.18 as of Aug. 05, 2026. This is near median its historical median of 14.28. Over the past decade, Tsumura's EV-to-OCF has ranged from 8.27 to 84.92. According to the industry distribution chart, Tsumura ranks #622 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 61.7%.
Is Tsumura's EV-to-OCF too high?
Tsumura's current EV-to-OCF of 15.18 is near median its 10-year median of 14.28. Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 84.92. The Drug Manufacturers industry median EV-to-OCF is 10.83. Tsumura's value of 15.18 is 40.2% above this industry median. Based on the distribution chart, Tsumura ranks #622 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tsumura has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Tsumura's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tsumura ranks #622 out of 1008 companies for EV-to-OCF. This places Tsumura in the lower half of its industry. The industry median EV-to-OCF is 10.83. Tsumura's value of 15.18 is 40.2% above this benchmark. Historically, Tsumura's own EV-to-OCF has ranged from 8.27 to 84.92 over the past decade. While the company's 10-year median is 14.28 vs. the industry median of 10.83, Tsumura has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsumura's current EV-to-OCF of 15.18 is 40.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsumura's current EV-to-OCF is 15.18, which is near median its own 10-year median of 14.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsumura stock overvalued right now?
Tsumura (TSMRF) has a current EV-to-OCF of 15.18. The stock's GF Value™ is $25.74, compared to a current price of $23.20 — trading 9.9% below its estimated fair value. The current EV-to-OCF is 15.18, which is near median its 10-year median of 14.28 and 40.2% above the Drug Manufacturers industry median of 10.83. Tsumura's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Tsumura (TSMRF), the current EV-to-OCF is 15.18 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsumura (TSMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Tsumura stock appears to be undervalued.
The current stock price of $23.20 is trading 9.9% below its estimated GF Value™ of $25.74.
Key valuation signals for TSMRF:
EV-to-OCF: 15.18 (near median its 10-year median of 14.28)
GF Value™: $25.74 vs. price of $23.20 (9.9% below fair value)
Industry Position: 40.2% above the Drug Manufacturers median (#622 of 1008)
No single metric tells the full story. See the TSMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.
79GF Score
Get the complete analysis for TSMRF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSMRF has been successfully added to your 
